Litcius/Paper detail

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero

2022Annals of Oncology81 citationsDOI

Topics & Concepts

MedicineCommon Terminology Criteria for Adverse EventsAdverse effectPharmacokineticsCarcinoembryonic antigenInternal medicinePopulationOncologyAntibody-drug conjugateAntibodyCancerPharmacologyGastroenterologyMonoclonal antibodyImmunologyEnvironmental healthRadiopharmaceutical Chemistry and ApplicationsHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study | Litcius